Form 4: Director Matthew J. Leonard Receives ANIP Stock Award

ANI Pharmaceuticals director Matthew J. Leonard was granted 4,357 shares of common stock via a restricted stock award.

Summary

• Director Matthew J. Leonard acquired 4,357 shares of ANI Pharmaceuticals, Inc. (ANIP) common stock.
• The transaction occurred on May 21, 2026, at a price of $0 per share.
• The acquisition represents a restricted stock award.
• Following this transaction, the director's total beneficial ownership is 11,221 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with shareholders through equity compensation.

Future Outlook

The restricted stock award is scheduled to vest in full on May 21, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term performance and align leadership with shareholder interests.

Comparison to Industry Standards

• The use of restricted stock awards for director compensation is consistent with standard practices in the pharmaceutical and biotechnology sectors.

Stakeholder Impact

• Minor increase in director equity stake, aligning interests with shareholders.

Next Steps

• Vesting of the 4,357 shares on May 21, 2027.

Key Dates

Keywords

ANIP, ANI Pharmaceuticals, Form 4, Insider Transaction, Restricted Stock Award